Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 16,821–16,840 of 17,987 drug recalls

Drug Recall Terminated Historical recordClass I

Piperacillin and Tazobactam for Injection, USP, 40.5 grams per Pharmacy Bulk Package vial, Rx only, Mfg. by: Hospira Healthcare India Pvt. Ltd., Irungattukottai - 602 105, India; Mfg. for: Apotex Corp., Weston, FL 33326, NDC 60505-0773-0

by Apotex Corp.

Reason
Crystallization: Potential to exhibit precipitation/crystallization in IV bag or IV line upon reconstitution.
Recall initiated
May 10, 2013
Reported by FDA
August 14, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass I

Lightning ROD capsules, 550 mg/capsule, packaged in 12-count bottles (UPC 6 89076 20297 8).

by Chang Kwung Products

Reason
Marketed Without An Approved NDA/ANDA: Lightning Rod capsules are being recalled because FDA analysis found it to contain an undeclared analogue of sildenafil. Sildenafil is the active ingredient in an FDA-approved product indicated for the treatment of male erectile dysfunction (ED), making this product an unapproved new drug.
Recall initiated
May 6, 2013
Reported by FDA
August 14, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass I

Lightning ROD capsules, 500 mg/capsule, packaged in 3-count bottles (UPC 6 89076 20257 2).

by Chang Kwung Products

Reason
Marketed Without An Approved NDA/ANDA: Lightning Rod capsules are being recalled because FDA analysis found it to contain an undeclared analogue of sildenafil. Sildenafil is the active ingredient in an FDA-approved product indicated for the treatment of male erectile dysfunction (ED), making this product an unapproved new drug.
Recall initiated
May 6, 2013
Reported by FDA
August 14, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass I

Methotrexate Injection, USP, Preservative-Free, 1 g/40 mL (25 mg/mL), 40 mL Single Dose Vial, Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540; Manufactured by: EBEWE Pharma Ges.m.b.H. Nfg.KG, A-4866 Unterach, AUSTRIA, NDC 66758-041-01.

by Sandoz Incorporated

Reason
Presence of Particulate Matter: Found during examination of retention samples.
Recall initiated
May 20, 2013
Reported by FDA
August 14, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015, Product L5B4826, NDC 0941-0409-07

by Baxter Healthcare Corp.

Reason
Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.
Recall initiated
July 24, 2013
Reported by FDA
August 7, 2013
Distribution
Nationwide and Puerto Rico

View recall →

Drug Recall Terminated Historical recordClass II

Olanzapine Tablets, USP, 10 mg, Rx Only, 30 tablets per bottle, Mfd for: Prasco Laboratories, Mason OH, 45040, USA, Mfd by: Torrent Pharmaceuticals Ltd., Indrad-382 721, Dist. Mehsana India, NDC 66993-463-30

by Torrent Pharma Inc

Reason
Defective Container; This action is being taken as a precautionary measure due to the product being re-packaged in the U.S. using a filler material that (removes or blocks) less moisture than what is approved in the application.
Recall initiated
July 22, 2013
Reported by FDA
August 7, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Ranitidine Syrup (Ranitidine Oral Solution USP) 15 mg/mL, Rx Only. Manufactured by VistaPharm, Inc., Birmingham, AL 35242. Distributed by Actavis Mid Atlantic LLC 1877 Kawai Road, Lincolnton, NC 28092 USA

by Actavis South Atlantic LLC

Reason
Failed Impurity/Degradation Specification; "Related Compound C"
Recall initiated
May 15, 2013
Reported by FDA
August 7, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass I

Night Bullet Capsules, supplied in 1 count packets, produced by Green Planet Inc, Riverside, CA

by Green Planet Inc

Reason
Marketed Without an Approved NDA/ANDA; product contains analogues of sildenafil and tadalafil which are active pharmaceutical ingredients in FDA-approved drugs used to treat erectile dysfunction (ED) making this product an unapproved new drug.
Recall initiated
March 11, 2013
Reported by FDA
August 7, 2013
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

DayQuil Sinex DayTime Sinus Relief (acetaminophen 325 mg and phenylephrine HCl 5 mg) liquicaps and NyQuil Sinex NightTime Sinus Relief (acetaminophen 325 mg, doxylamine succinate 6.25 mg, and phenylephrine HCl 5 mg) liquicaps Combopack, each 48-count liquicaps per carton contains 32 DayQuil Sinex DayTime Liquicaps and 16 NyQuil Sinex NightTime Liquicaps per carton, Made In Canada, Dist. by Procter & Gamble, Cincinnati, OH 45202, UPC 3 23900 01454 1.

by Procter & Gamble Co

Reason
Unit Dose Mispackaging: Product packaging defect which could result in code date smearing, incomplete blister card cuts, and missing or incorrectly placed liquicaps within the blisters.
Recall initiated
July 3, 2013
Reported by FDA
August 7, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Belladonna Alkaloids/PB (Belladonna Alkaloids / Phenobarbital) Tablets Phenobarbital USP 16.2 mg, Hyoscyamine Sulfate 0.1037 mg, Atropine Sulfate 0.0194 mg, Scopolamine Hydrobromide 0.0065 mg 30-count bottle (NDC 54868-0031-04), Rx only, Repackaged and distributed by Physicians Total Care, Inc. Tulsa, OK 74146.

by Physicians Total Care, Inc.

Reason
Presence of Foriegn Substance:The manufacturer, West-ward Pharmaceutical, recalled product because of the presence of black spots on tablets. In response, the repackager initiated its own recall.
Recall initiated
June 17, 2013
Reported by FDA
August 7, 2013
Distribution
GA

View recall →

Drug Recall Terminated Historical recordClass II

Enablex (darifenacin) Extended Release Tablet, 15 mg per tablet. Physician Sample 7 Tablets bottle, Rx only, Mfd by: Novartis Pharma Stein AG, Stein, Switzerland, NDC 0078-9420-07

by Warner Chilcott US LLC

Reason
Failed Impurities/Degradation Specifications: unspecified degradation product
Recall initiated
May 17, 2013
Reported by FDA
August 7, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

West-ward Belladonna Alkaloids with Phenobarbital Tablets, a) 1000-count bottle (NDC 0143-1140-10),Rx only, Manufactured by West-ward Pharmacuetical Corp., Eatontown, N.J., 07724

by West-Ward Pharmaceutical Corp.

Reason
Cross contamination with other products: Belladonna Alkaloids with Phenobarbital Tablets contained a trace amount of Methocarbamol.
Recall initiated
May 16, 2013
Reported by FDA
July 31, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

West-ward Belladonna Alkaloids with Phenobarbital Tablets, a) 1000-count bottle (NDC 0143-1140-10), b) 5000-count bottle (NDC 0143-1140-51), Rx only, Manufactured by West-ward Pharmaceutical Corp., Eatontown, N.J., 07724

by West-Ward Pharmaceutical Corp.

Reason
Presence of Foreign Substance: Belladonna Alkaloids with Phenobarbital Tablets with black specks comprised of degraded organic material on tablets.
Recall initiated
May 16, 2013
Reported by FDA
July 31, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass III

Oxycodone and Acetaminophen Capsules, USP 5mg/500 mg, packaged in a)100-count bottle (NDC 0591-0737-01), b) 500-count bottle (NDC 0591-0737-05), Rx only, Manufactured by Watson Laboratories, Inc., Corona, CA92880.

by Watson Laboratories Inc

Reason
Subpotent drug: Two lots of Oxycodone and Acetaminophen Capsules, USP 5/500 mg are being recalled due to low out of specification (OOS) assay result obtained at expiry (24 months) for the oxycodone portion of the product.
Recall initiated
July 19, 2013
Reported by FDA
July 31, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

AmBisome (amphotericin B) liposome for Injection, 50 mg, For Intravenous Infusion Only, Single-Use Vial, Rx Only, Marketed by: Astellas Pharma US, Inc., Northbrook, IL 60062, Manufactured by: Gilead Sciences, Inc., San Dimas, CA 91773, NDC 0469-3051-30.

by Gilead Sciences, Inc.

Reason
Lack of Sterility Assurance; During a routine simulation of the manufacturing of AmBisome, a bacterial contamination was detected in some media fill units. No contaminated batches have actually been identified in the finished product, but there is a possibility of contamination.
Recall initiated
June 20, 2013
Reported by FDA
July 31, 2013
Distribution
Foreign distribution only to France, Italy, Switzerland, Portugal, Denmark,Turkey, Ireland, Norway, Malta, UK, Greece, Belgium, Austria, Germany, India, Hong Kong, Israel, Saudi Arabia, Thailand, UAE, Singapore, Ecuador, Oman, El Salvador, MCF Holland, MSF, France, Ethiopia, Egypt, Argentina, Chile, Brazil, Spain, Finland, Sweden.

View recall →

Drug Recall Terminated Historical recordClass II

AmBisome (amphotericin B) liposome for injection, 50mg vial, single use vial, For Intravenous Infusion Only, Rx Only, Marketed by: Astellas Pharma US, Inc., Northbrook, IL 60062, Manufactured by: Gilead Sciences, Inc, San Dimas, CA 91773, NDC: 0469-3051-30.

by Astellas Pharma US Inc

Reason
Lack of Assurance of Sterility; Astellas Pharma US, Inc. is performing a voluntary recall on certain lots of AmBisome because the manufacturer has notified Astellas that during a routine simulation of the manufacturing of AmBisome, a bacterial contamination was detected in the media fills.
Recall initiated
June 19, 2013
Reported by FDA
July 31, 2013
Distribution
Nationwide and Canada

View recall →

Drug Recall Terminated Historical recordClass II

VIVITROL (naltrexone for extended-release injectable suspension) a) 380 mg vial NDC 65757-303-02, b) 380 mg vial in kit NDC 65757-300-01, Rx Only Manufactured and marketed by Alkermes, Inc., Waltham, MA 02451,

by Alkermes, Inc.

Reason
Lack of Assurance of Sterility: Product did not meet the criteria for container closure integrity testing during routine 24 month stability testing.
Recall initiated
November 6, 2012
Reported by FDA
July 31, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Oxygen, Compressed USP UN1072 Medical Gas supplied in a) 682 litres and b)165 litres cylinders, Rx only, Oklahoma Respiratory Care 800.262.9857, Norman, OK 73071

by Oklahoma Respiratory Care Inc

Reason
Failed impurities/degradation specifications: Purity readings for oxygen were out of specification.
Recall initiated
December 5, 2012
Reported by FDA
July 31, 2013
Distribution
Oklahoma

View recall →

Drug Recall Terminated Historical recordClass II

Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75mg/0.2mg, 60-count bottle, Rx only, Manufactured by Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60

by Watson Laboratories, Inc.-(Actavis) - Florida

Reason
Failed Tablet/Capsule Specifications: Broken tablets
Recall initiated
March 22, 2013
Reported by FDA
July 31, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass III

LA MER the spf 18 fluid tint , broad spectrum spf 18, 1.7 fl.oz. liq./50 ml, Shade DARK 04, UPC 7 47930 00483 7 --- MAX HUBER RESEARCH LABS INC., DIST. NEW YORK, N.Y. 10022 -- MADE IN BELGIUM

by Max Huber Research Labs, Inc.

Reason
Subpotent drug: Avobenzone 3%, one of the active sunscreen ingredients may be subpotent and sunscreen effectiveness may be less than labeled
Recall initiated
June 27, 2013
Reported by FDA
July 31, 2013
Distribution
Nationwide

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.